{
  "symbol": "AMGN",
  "year": 2022,
  "period": "Q3",
  "competition_summary": [
    {
      "competitor": "ENBREL",
      "mentions": 2,
      "context": "competition. In addition, in the first quarter of 2022, ENBREL and Otezla followed the historic pattern of lower first quarter sales relative to the remainder of the year due to the impact of benefit plan changes, insurance reverifications and increased co-pay expenses as U.S. patients work through deductibles. Throughout the COVID-19 pandemic, we experienced changes in demand for some of our products. The pandemic has interrupted many physician\u2013patient interactions, which has led to delays in d"
    },
    {
      "competitor": "COVID-19",
      "mentions": 5,
      "context": "competition. In addition, in the first quarter of 2022, ENBREL and Otezla followed the historic pattern of lower first quarter sales relative to the remainder of the year due to the impact of benefit plan changes, insurance reverifications and increased co-pay expenses as U.S. patients work through deductibles. Throughout the COVID-19 pandemic, we experienced changes in demand for some of our products. The pandemic has interrupted many physician\u2013patient interactions, which has led to delays in d"
    },
    {
      "competitor": "Omicron",
      "mentions": 1,
      "context": "competition. In addition, in the first quarter of 2022, ENBREL and Otezla followed the historic pattern of lower first quarter sales relative to the remainder of the year due to the impact of benefit plan changes, insurance reverifications and increased co-pay expenses as U.S. patients work through deductibles. Throughout the COVID-19 pandemic, we experienced changes in demand for some of our products. The pandemic has interrupted many physician\u2013patient interactions, which has led to delays in d"
    },
    {
      "competitor": "Medicaid",
      "mentions": 1,
      "context": "competition. In addition, in the first quarter of 2022, ENBREL and Otezla followed the historic pattern of lower first quarter sales relative to the remainder of the year due to the impact of benefit plan changes, insurance reverifications and increased co-pay expenses as U.S. patients work through deductibles. Throughout the COVID-19 pandemic, we experienced changes in demand for some of our products. The pandemic has interrupted many physician\u2013patient interactions, which has led to delays in d"
    },
    {
      "competitor": "Management\u2019s Discussion and Analysis of Financial Condition",
      "mentions": 2,
      "context": "competition. In addition, in the first quarter of 2022, ENBREL and Otezla followed the historic pattern of lower first quarter sales relative to the remainder of the year due to the impact of benefit plan changes, insurance reverifications and increased co-pay expenses as U.S. patients work through deductibles. Throughout the COVID-19 pandemic, we experienced changes in demand for some of our products. The pandemic has interrupted many physician\u2013patient interactions, which has led to delays in d"
    },
    {
      "competitor": "Results of Operations",
      "mentions": 1,
      "context": "competition. In addition, in the first quarter of 2022, ENBREL and Otezla followed the historic pattern of lower first quarter sales relative to the remainder of the year due to the impact of benefit plan changes, insurance reverifications and increased co-pay expenses as U.S. patients work through deductibles. Throughout the COVID-19 pandemic, we experienced changes in demand for some of our products. The pandemic has interrupted many physician\u2013patient interactions, which has led to delays in d"
    },
    {
      "competitor": "ROW",
      "mentions": 11,
      "context": "competition. In addition, in the first quarter of 2022, ENBREL and Otezla followed the historic pattern of lower first quarter sales relative to the remainder of the year due to the impact of benefit plan changes, insurance reverifications and increased co-pay expenses as U.S. patients work through deductibles. Throughout the COVID-19 pandemic, we experienced changes in demand for some of our products. The pandemic has interrupted many physician\u2013patient interactions, which has led to delays in d"
    },
    {
      "competitor": "Otezla Total Otezla",
      "mentions": 1,
      "context": "competition. In addition, in the first quarter of 2022, ENBREL and Otezla followed the historic pattern of lower first quarter sales relative to the remainder of the year due to the impact of benefit plan changes, insurance reverifications and increased co-pay expenses as U.S. patients work through deductibles. Throughout the COVID-19 pandemic, we experienced changes in demand for some of our products. The pandemic has interrupted many physician\u2013patient interactions, which has led to delays in d"
    },
    {
      "competitor": "Contingencies",
      "mentions": 5,
      "context": "competition. In addition, in the first quarter of 2022, ENBREL and Otezla followed the historic pattern of lower first quarter sales relative to the remainder of the year due to the impact of benefit plan changes, insurance reverifications and increased co-pay expenses as U.S. patients work through deductibles. Throughout the COVID-19 pandemic, we experienced changes in demand for some of our products. The pandemic has interrupted many physician\u2013patient interactions, which has led to delays in d"
    },
    {
      "competitor": "Aranesp Total Aranesp",
      "mentions": 1,
      "context": "competition. In addition, in the first quarter of 2022, ENBREL and Otezla followed the historic pattern of lower first quarter sales relative to the remainder of the year due to the impact of benefit plan changes, insurance reverifications and increased co-pay expenses as U.S. patients work through deductibles. Throughout the COVID-19 pandemic, we experienced changes in demand for some of our products. The pandemic has interrupted many physician\u2013patient interactions, which has led to delays in d"
    },
    {
      "competitor": "ESA",
      "mentions": 1,
      "context": "competition. In addition, in the first quarter of 2022, ENBREL and Otezla followed the historic pattern of lower first quarter sales relative to the remainder of the year due to the impact of benefit plan changes, insurance reverifications and increased co-pay expenses as U.S. patients work through deductibles. Throughout the COVID-19 pandemic, we experienced changes in demand for some of our products. The pandemic has interrupted many physician\u2013patient interactions, which has led to delays in d"
    },
    {
      "competitor": "EPOGEN",
      "mentions": 1,
      "context": "competition. In addition, in the first quarter of 2022, ENBREL and Otezla followed the historic pattern of lower first quarter sales relative to the remainder of the year due to the impact of benefit plan changes, insurance reverifications and increased co-pay expenses as U.S. patients work through deductibles. Throughout the COVID-19 pandemic, we experienced changes in demand for some of our products. The pandemic has interrupted many physician\u2013patient interactions, which has led to delays in d"
    },
    {
      "competitor": "Neulasta Total Neulasta",
      "mentions": 1,
      "context": "competition. In addition, in the first quarter of 2022, ENBREL and Otezla followed the historic pattern of lower first quarter sales relative to the remainder of the year due to the impact of benefit plan changes, insurance reverifications and increased co-pay expenses as U.S. patients work through deductibles. Throughout the COVID-19 pandemic, we experienced changes in demand for some of our products. The pandemic has interrupted many physician\u2013patient interactions, which has led to delays in d"
    },
    {
      "competitor": "Neulasta",
      "mentions": 1,
      "context": "competition. In addition, in the first quarter of 2022, ENBREL and Otezla followed the historic pattern of lower first quarter sales relative to the remainder of the year due to the impact of benefit plan changes, insurance reverifications and increased co-pay expenses as U.S. patients work through deductibles. Throughout the COVID-19 pandemic, we experienced changes in demand for some of our products. The pandemic has interrupted many physician\u2013patient interactions, which has led to delays in d"
    },
    {
      "competitor": "Onpro",
      "mentions": 1,
      "context": "competition. In addition, in the first quarter of 2022, ENBREL and Otezla followed the historic pattern of lower first quarter sales relative to the remainder of the year due to the impact of benefit plan changes, insurance reverifications and increased co-pay expenses as U.S. patients work through deductibles. Throughout the COVID-19 pandemic, we experienced changes in demand for some of our products. The pandemic has interrupted many physician\u2013patient interactions, which has led to delays in d"
    },
    {
      "competitor": "Repatha Total Repatha",
      "mentions": 1,
      "context": "competition. In addition, in the first quarter of 2022, ENBREL and Otezla followed the historic pattern of lower first quarter sales relative to the remainder of the year due to the impact of benefit plan changes, insurance reverifications and increased co-pay expenses as U.S. patients work through deductibles. Throughout the COVID-19 pandemic, we experienced changes in demand for some of our products. The pandemic has interrupted many physician\u2013patient interactions, which has led to delays in d"
    },
    {
      "competitor": "Medicare",
      "mentions": 1,
      "context": "competition. In addition, in the first quarter of 2022, ENBREL and Otezla followed the historic pattern of lower first quarter sales relative to the remainder of the year due to the impact of benefit plan changes, insurance reverifications and increased co-pay expenses as U.S. patients work through deductibles. Throughout the COVID-19 pandemic, we experienced changes in demand for some of our products. The pandemic has interrupted many physician\u2013patient interactions, which has led to delays in d"
    },
    {
      "competitor": "FDA",
      "mentions": 1,
      "context": "competition. In addition, in the first quarter of 2022, ENBREL and Otezla followed the historic pattern of lower first quarter sales relative to the remainder of the year due to the impact of benefit plan changes, insurance reverifications and increased co-pay expenses as U.S. patients work through deductibles. Throughout the COVID-19 pandemic, we experienced changes in demand for some of our products. The pandemic has interrupted many physician\u2013patient interactions, which has led to delays in d"
    },
    {
      "competitor": "Nplate Total Nplate",
      "mentions": 1,
      "context": "competition. In addition, in the first quarter of 2022, ENBREL and Otezla followed the historic pattern of lower first quarter sales relative to the remainder of the year due to the impact of benefit plan changes, insurance reverifications and increased co-pay expenses as U.S. patients work through deductibles. Throughout the COVID-19 pandemic, we experienced changes in demand for some of our products. The pandemic has interrupted many physician\u2013patient interactions, which has led to delays in d"
    },
    {
      "competitor": "EVENITY",
      "mentions": 2,
      "context": "competition. In addition, in the first quarter of 2022, ENBREL and Otezla followed the historic pattern of lower first quarter sales relative to the remainder of the year due to the impact of benefit plan changes, insurance reverifications and increased co-pay expenses as U.S. patients work through deductibles. Throughout the COVID-19 pandemic, we experienced changes in demand for some of our products. The pandemic has interrupted many physician\u2013patient interactions, which has led to delays in d"
    },
    {
      "competitor": "LUMAKRAS",
      "mentions": 1,
      "context": "competition. In addition, in the first quarter of 2022, ENBREL and Otezla followed the historic pattern of lower first quarter sales relative to the remainder of the year due to the impact of benefit plan changes, insurance reverifications and increased co-pay expenses as U.S. patients work through deductibles. Throughout the COVID-19 pandemic, we experienced changes in demand for some of our products. The pandemic has interrupted many physician\u2013patient interactions, which has led to delays in d"
    },
    {
      "competitor": "NEUPOGEN",
      "mentions": 1,
      "context": "competition. In addition, in the first quarter of 2022, ENBREL and Otezla followed the historic pattern of lower first quarter sales relative to the remainder of the year due to the impact of benefit plan changes, insurance reverifications and increased co-pay expenses as U.S. patients work through deductibles. Throughout the COVID-19 pandemic, we experienced changes in demand for some of our products. The pandemic has interrupted many physician\u2013patient interactions, which has led to delays in d"
    },
    {
      "competitor": "NA Sensipar/Mimpara",
      "mentions": 1,
      "context": "competition. In addition, in the first quarter of 2022, ENBREL and Otezla followed the historic pattern of lower first quarter sales relative to the remainder of the year due to the impact of benefit plan changes, insurance reverifications and increased co-pay expenses as U.S. patients work through deductibles. Throughout the COVID-19 pandemic, we experienced changes in demand for some of our products. The pandemic has interrupted many physician\u2013patient interactions, which has led to delays in d"
    },
    {
      "competitor": "NA",
      "mentions": 1,
      "context": "competition. In addition, in the first quarter of 2022, ENBREL and Otezla followed the historic pattern of lower first quarter sales relative to the remainder of the year due to the impact of benefit plan changes, insurance reverifications and increased co-pay expenses as U.S. patients work through deductibles. Throughout the COVID-19 pandemic, we experienced changes in demand for some of our products. The pandemic has interrupted many physician\u2013patient interactions, which has led to delays in d"
    },
    {
      "competitor": "SG&A",
      "mentions": 1,
      "context": "competition. In addition, in the first quarter of 2022, ENBREL and Otezla followed the historic pattern of lower first quarter sales relative to the remainder of the year due to the impact of benefit plan changes, insurance reverifications and increased co-pay expenses as U.S. patients work through deductibles. Throughout the COVID-19 pandemic, we experienced changes in demand for some of our products. The pandemic has interrupted many physician\u2013patient interactions, which has led to delays in d"
    },
    {
      "competitor": "Administration",
      "mentions": 1,
      "context": "competition. In addition, in the first quarter of 2022, ENBREL and Otezla followed the historic pattern of lower first quarter sales relative to the remainder of the year due to the impact of benefit plan changes, insurance reverifications and increased co-pay expenses as U.S. patients work through deductibles. Throughout the COVID-19 pandemic, we experienced changes in demand for some of our products. The pandemic has interrupted many physician\u2013patient interactions, which has led to delays in d"
    },
    {
      "competitor": "Congress",
      "mentions": 1,
      "context": "competition. In addition, in the first quarter of 2022, ENBREL and Otezla followed the historic pattern of lower first quarter sales relative to the remainder of the year due to the impact of benefit plan changes, insurance reverifications and increased co-pay expenses as U.S. patients work through deductibles. Throughout the COVID-19 pandemic, we experienced changes in demand for some of our products. The pandemic has interrupted many physician\u2013patient interactions, which has led to delays in d"
    },
    {
      "competitor": "OECD",
      "mentions": 1,
      "context": "competition. In addition, in the first quarter of 2022, ENBREL and Otezla followed the historic pattern of lower first quarter sales relative to the remainder of the year due to the impact of benefit plan changes, insurance reverifications and increased co-pay expenses as U.S. patients work through deductibles. Throughout the COVID-19 pandemic, we experienced changes in demand for some of our products. The pandemic has interrupted many physician\u2013patient interactions, which has led to delays in d"
    },
    {
      "competitor": "The U.S. Treasury",
      "mentions": 1,
      "context": "competition. In addition, in the first quarter of 2022, ENBREL and Otezla followed the historic pattern of lower first quarter sales relative to the remainder of the year due to the impact of benefit plan changes, insurance reverifications and increased co-pay expenses as U.S. patients work through deductibles. Throughout the COVID-19 pandemic, we experienced changes in demand for some of our products. The pandemic has interrupted many physician\u2013patient interactions, which has led to delays in d"
    }
  ]
}